This package contains three reports analyzing
as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:
The reports describe and discuss
Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
CD123: a paradigmatic target for immunotherapeutic treatment modalities
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.
Tables of Content
Report 1:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape
Company Profiles
References
Report 2:
CD123: a paradigmatic target for immunotherapeutic treatment modalities
Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics
Report 3:
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics
*If Applicable.